[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cardiff Oncology Inc 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 USA

https://cardiffoncology.com Employees: 31 P: 858-952-7570

Sector:

Medical

Description:

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.

Key Statistics

Overview:

Market Capitalization, $K 114,178
Enterprise Value, $K 96,708
Shares Outstanding, K 68,370
Float, K 63,106
% Float 92.30%
Short Interest, K 18,322
Short Float 26.80%
Days to Cover 22.21
Short Volume Ratio 0.53
% of Insider Shareholders 7.70%
% of Institutional Shareholders 16.29%

Financials:

Annual Sales, $ 590 K
Annual Net Income, $ -45,850 K
Last Quarter Sales, $ 240 K
Last Quarter Net Income, $ -7,220 K
EBIT, $ -48,960 K
EBITDA, $ -49,440 K

Growth:

1-Year Return -39.27%
3-Year Return -1.76%
5-Year Return -78.78%
5-Year Revenue Growth 59.46%
5-Year Earnings Growth 36.11%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.11 on 02/24/26
Next Earnings Date 08/04/26
Earnings Per Share ttm -0.69
EPS Growth vs. Prev Qtr -63.64%
EPS Growth vs. Prev Year 10.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 02/20/19

CRDF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -87.91%
Return-on-Assets % -66.69%
Profit Margin % -7,771.19%
Debt/Equity 0.00
Price/Sales 199.46
Price/Cash Flow N/A
Price/Book 2.57
Book Value/Share 0.67
Interest Coverage -2.22
60-Month Beta 1.36
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.